tirzepatide news september 27 2025 Lilly's new weight-loss drug is a 'double wow' and likely blockbuster – Indianapolis Business Journal Lilly hikes revenue forecasts on

Effects of canagliflozin on fatty liver indexes in patients with type 2 diabetes: a meta-analysis of randomized controlled trials

I meccanismi alla base di nausea/vomito e diarrea non sono completamente compresi

The Complicated Reality Behind GLP-1 Drugs Part of the confusion surrounding these medications comes from the difference between brand-name drugs and the growing market for compounded versions

Why Direct Meds Is Specifically Well-Positioned for Coverage-Loss Patients Direct Meds' combination of features makes it particularly well-suited for the coverage-loss patient population in a way that most competing platforms are not simultaneously

The new insulin-stimulating weight-loss drugs semaglutide and tirzepatide appear impressive

Yet we still have taste receptors from an era when craving sweet tastes had few drawbacks besides getting stung by bees, making that extra block of chocolate or sweet drink hard to resist